INTRAVENOUS GLYCERYL TRINITRATE IS A VALUABLE TOOL

InPharma ◽  
1978 ◽  
Vol 160 (1) ◽  
pp. 17-18
Keyword(s):  
Glyceryl Trinitrate ◽  
Intravenous Glyceryl Trinitrate

scholarly journals Reduction of infarct size in patients with inferior infarction with intravenous glyceryl trinitrate. A randomised study.

Heart ◽  
1983 ◽  
Vol 49 (5) ◽  
pp. 452-460 ◽  
Author(s):  
A S Jaffe ◽  
E M Geltman ◽  
A J Tiefenbrunn ◽  
H D Ambos ◽  
H D Strauss ◽  
...  
Keyword(s):  
Infarct Size ◽  
Glyceryl Trinitrate ◽  
Randomised Study ◽  
Intravenous Glyceryl Trinitrate

Safety of Intravenous Glyceryl Trinitrate in Management of Retained Placenta

1997 ◽  
Vol 52 (11) ◽  
pp. 676-677
Author(s):  
Isaac P. Lowenwirt ◽  
Rose M. Zauk ◽  
Sara M. Handwerker
Keyword(s):  
Glyceryl Trinitrate ◽  
Retained Placenta ◽  
Intravenous Glyceryl Trinitrate

scholarly journals Rapid Intravenous Glyceryl Trinitrate in Ischemic Damage (RIGID) After Stroke: Rationale, Design and Protocol for a Prospective Randomized Controlled Trial

2021 ◽  
Vol 12 ◽  
Author(s):  
Lipeng Cai ◽  
Gary Rajah ◽  
Honglian Duan ◽  
Jie Gao ◽  
Zhe Cheng ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Glyceryl Trinitrate ◽  
Intravenous Administration ◽  
Controlled Trial ◽  
Intravenous Thrombolysis ◽  
Control Group ◽  
Ischemic Damage ◽  
Randomized Controlled ◽  
Prospective Randomized Controlled Trial ◽  
Intravenous Glyceryl Trinitrate

Background: Despite intravenous thrombolysis and endovascular therapy for acute ischemic stroke (AIS), many survivors still have varying degrees of disability. Glyceryl trinitrate (GTN), a nitric oxide (NO) donor, has been previously reported to induce neuroprotection after AIS. The use of GTN to reduce brain damage after stroke remains yet to be elucidated. This study was designed to explore the safety, feasibility, and preliminary efficacy of intravenous administration of GTN after AIS.Methods: A prospective randomized controlled trial is proposed with AIS patients. Participants will be randomly allocated to GTN group and control group with a 1:1 ratio (n = 40). Both groups will be treated with standard therapies according to the current stroke guidelines. Participants allocated to the GTN group will receive intravenous administration of GTN (5 mg GTN in 50 ml saline at a rate of 0.4 mg/h that is continued for 12.5 h/day for 2 days) within 24 h of symptom onset. Participants allocated to the control group will receive intravenous administration at equal capacity of 0.9% normal saline (NS) (total 50 ml/day at 4 ml/h that is continued for 12.5 h/day for 2 days). The primary outcome is safety [systolic blood pressure (SBP) <110 mmHg, headache], while the secondary outcomes include changes in functional outcome and infarction volume.Discussion: Rapid Intravenous Glyceryl Trinitrate in Ischemic Damage (RIGID) is a prospective randomized controlled trial that aims to ascertain the safety, feasibility, and preliminary efficacy of intravenous GTN as a neuroprotection strategy after AIS. These results will provide parameters for future studies as well as provide insights into treatment effects. Any possible neuroprotective qualities of GTN in AIS will also be elucidated.Trial Registration:www.chictr.org.cn, identifier: ChiCTR2100046271.

Sign in / Sign up

Export Citation Format

Share Document